{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:45Z","timestamp":1793505465076,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["OI 172044"],"award-info":[{"award-number":["OI 172044"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["TR 31060"],"award-info":[{"award-number":["TR 31060"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.pharmthera.2016.07.009","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T07:08:51Z","timestamp":1469948931000},"page":"100-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors"],"prefix":"10.1016","volume":"167","author":[{"given":"Marko","family":"Anderluh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Kocic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Tomovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radivoj","family":"Kocic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Deljanin-Ilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrija","family":"Smelcerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.07.009_bb0005","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1161\/01.CIR.0000147780.30124.CF","article-title":"Stromal cell-derived factor-1\u03b1 plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury","volume":"110","author":"Abbott","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0010","doi-asserted-by":"crossref","first-page":"H477","DOI":"10.1152\/ajpheart.00209.2014","article-title":"Pleiotropic effects of the dipeptidyl peptidase-4 inhibitors on the cardiovascular system","volume":"307","author":"Aroor","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0015","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(03)14232-8","article-title":"Effect of stromal-cell derived factor-1 on stem cell homing and tissue regeneration in ischemic cardiomyopathy","volume":"362","author":"Askari","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0020","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/0929867053507298","article-title":"The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidylaminopeptidases","volume":"12","author":"Augustyns","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0025","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","article-title":"DPP-4 inhibitors and their potential role in the management of type 2 diabetes","volume":"60","author":"Barnett","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0030","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","article-title":"Regulation of CXCR4 signaling","volume":"1768","author":"Busillo","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0196-9781(94)90211-9","article-title":"Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences","volume":"15","author":"Campbell","year":"1994","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/cvr\/cvs132","article-title":"The SDF-1\/CXCR4 axis in stem cell preconditioning","volume":"94","author":"Cencioni","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0045","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.yjmcc.2008.01.004","article-title":"Homing and engraftment of progenitor cells: a prerequisite for cell therapy","volume":"45","author":"Chavakis","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0050","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischemic heart failure patients: the STOP-HF randomized phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1753-0407.12258","article-title":"Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: role of stromal cell-derived factor-1\u03b1","volume":"8","author":"Connelly","year":"2016","journal-title":"J Diabetes"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0060","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1093\/emboj\/16.23.6996","article-title":"Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1","volume":"16","author":"Crump","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.exger.2009.12.004","article-title":"Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice","volume":"45","author":"D'Amico","year":"2010","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0070","first-page":"1213","article-title":"CD26: an expanding role in immune regulation and cancer","volume":"17","author":"Dang","year":"2002","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0075","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0167-5699(99)01486-3","article-title":"CD26, let it cut or cut it down","volume":"20","author":"DeMeester","year":"1999","journal-title":"Immunol Today"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCULATIONAHA.111.082453","article-title":"Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction","volume":"126","author":"Dong","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0085","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12325-008-0076-1","article-title":"DPP4 inhibitors: a new approach in diabetes treatment","volume":"25","author":"Doupis","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0090","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","article-title":"Cardiovascular effects of DPP-4 inhibition: beyond GLP-1","volume":"55","author":"Fadini","year":"2011","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-015-0294-0","article-title":"Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes","volume":"14","author":"Fisman","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0105","doi-asserted-by":"crossref","first-page":"23169","DOI":"10.1074\/jbc.273.36.23169","article-title":"The \u03b1-chemokine, stromal cell-derived factor-1\u03b1, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways","volume":"273","author":"Ganju","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2006.10.004","article-title":"On the role of prolyloligopeptidase in health and disease","volume":"41","author":"Garcia-Horsman","year":"2007","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2010.09.011","article-title":"SDF-1\u03b1 as a therapeutic stem cell homing factor in myocardial infarction","volume":"129","author":"Ghadge","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/806979","article-title":"The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a \u201cme too\u201d or \u201cthe special one\u201d antidiabetic class?","author":"Godinho","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/CS20040302","article-title":"Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders","volume":"108","author":"Gorrell","year":"2005","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0014-4827(88)90378-3","article-title":"Direct evidence for the binding of rat liver DPP IV to collagen in vitro","volume":"178","author":"Hanski","year":"1988","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS19990368","article-title":"A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence","volume":"99","author":"Hildebrandt","year":"2000","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0140","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0145","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1476-5381.2012.02102.x","article-title":"Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0150","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.4103\/2230-8210.104050","article-title":"What the future holds for gliptins","volume":"16","author":"Jindal","year":"2012","journal-title":"Indian J Endocr Metab"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/bj1570169","article-title":"Dipeptidyl peptidase IV, a kidney brush-border serine peptidase","volume":"155","author":"Kenny","year":"1976","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1042\/CS20090047","article-title":"Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition","volume":"118","author":"Kirby","year":"2010","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0165","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/stemcells.2004-0342","article-title":"Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis","volume":"23","author":"Kucia","year":"2005","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2004.10.014","article-title":"Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1\u03b1 (SDF-1\u03b1) treatment","volume":"125","author":"Liang Tang","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.regpep.2004.06.001","article-title":"Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?","volume":"128","author":"McIntosh","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26) \u2014 role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0185","first-page":"146","article-title":"Dipeptidyl peptidase-4 inhibitors: a new approach in diabetes treatment","volume":"1","author":"Monika","year":"2009","journal-title":"Int J Drug Dev Res"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","article-title":"A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site","volume":"434","author":"Nabeno","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0195","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ejmech.2013.12.038","article-title":"Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors","volume":"74","author":"Patel","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0200","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1590\/S0100-879X2003000500003","article-title":"Dipeptidyl peptidase IV (CD26) activity in the hematopoietic system: differences between the membrane-anchored and the released enzyme activity","volume":"36","author":"Pereira","year":"2003","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0205","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/jm8008597","article-title":"Covalent modifiers: an orthogonal approach to drug design","volume":"52","author":"Potashman","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nsb882","article-title":"Crystal structure of human dipeptidyl peptidase IV\/CD26 in complex with a substrate analog","volume":"10","author":"Rasmussen","year":"2003","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0215","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/prot.21350","article-title":"Crystal structure of recombinant human stromal cell-derived factor-1\u03b1","volume":"67","author":"Ryu","year":"2007","journal-title":"Proteins Srtuct Funct Bioinf"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tcm.2006.01.006","article-title":"SDF-1\u03b1-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine?","volume":"16","author":"Schober","year":"2006","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0225","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1161\/CIRCULATIONAHA.107.718718","article-title":"Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction","volume":"116","author":"Segers","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/(SICI)1098-2825(1996)10:6<435::AID-JCLA21>3.0.CO;2-X","article-title":"Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties","volume":"10","author":"Shibuya-Saruta","year":"1996","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0235","first-page":"465","article-title":"Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells","volume":"80","author":"Stefanovic","year":"1993","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0240","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0021-9258(19)40041-0","article-title":"Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains","volume":"265","author":"Tiruppathi","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0245","doi-asserted-by":"crossref","first-page":"ra4","DOI":"10.1126\/scisignal.1160755","article-title":"Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1\/CXCL12","volume":"1","author":"Veldkamp","year":"2008","journal-title":"Sci Signal"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0250","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jmb.2006.04.052","article-title":"Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1\u03b1 (SDF-1\u03b1\/CXCL12)","volume":"359","author":"Veldkamp","year":"2006","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0255","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/pro.167","article-title":"Monomeric structure of the cardioprotective chemokine SDF-1\/CXCL12","volume":"18","author":"Veldkamp","year":"2009","journal-title":"Protein Sci"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0260","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1096\/fasebj.13.13.1699","article-title":"The chemokine SDF-1\u03b1 triggers CXCR4 receptor dimerization and activates the JAK\/STAT pathway","volume":"13","author":"Vila-Coro","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0265","first-page":"20","article-title":"SDF-1\u03b1 and CXCR4 as therapeutic targets in cardiovascular disease","volume":"2","author":"Wen","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0270","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tips.2009.08.003","article-title":"Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?","volume":"30","author":"Yazbeck","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2009.02.013","article-title":"Synergy between CD26\/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction","volume":"4","author":"Zaruba","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0280","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1096\/fj.06-6558com","article-title":"SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction","volume":"21","author":"Zhang","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2016.07.009_bb0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1753-0407.12063","article-title":"Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs","volume":"6","author":"Zhao","year":"2014","journal-title":"J Diabetes"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:51:14Z","timestamp":1655387474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816301346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":57,"alternative-id":["S0163725816301346"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.07.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}